• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21936 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     Agency for Care Effectiveness (ACE) Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019     Agency for Care Effectiveness (ACE) Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019     Agency for Care Effectiveness (ACE) Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2020     Agency for Care Effectiveness (ACE) Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2019     Agency for Care Effectiveness (ACE) Febuxostat for treating chronic hyperuricaemia in adults with gout
2020     Agency for Care Effectiveness (ACE) Ursodeoxycholic acid for treating primary biliary cirrhosis
2019     Agency for Care Effectiveness (ACE) Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019     Agency for Care Effectiveness (ACE) Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019     Agency for Care Effectiveness (ACE) Oral COX-2 inhibitors for treating pain
2019     Agency for Care Effectiveness (ACE) Ferric carboxymaltose for treating iron deficiency anaemia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating cervical dystonia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019     Agency for Care Effectiveness (ACE) Endothelin receptor antagonists for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020     Agency for Care Effectiveness (ACE) Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020     Agency for Care Effectiveness (ACE) Epoprostenol for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Vonoprazan for treating helicobacter pylori infection
2020     Agency for Care Effectiveness (ACE) Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2020     Agency for Care Effectiveness (ACE) Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020     Agency for Care Effectiveness (ACE) Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020     Agency for Care Effectiveness (ACE) Mycophenolate mofetil for immunosuppression
2020     Agency for Care Effectiveness (ACE) Adalimumab for treating inflammatory conditions
2020     Agency for Care Effectiveness (ACE) Abiraterone for treating metastatic prostate cancer
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2021     Agency for Care Effectiveness (ACE) Tenofovir alafenamide for treating chronic hepatitis B infection
2021     Agency for Care Effectiveness (ACE) Metformin extended release for treating type 2 diabetes mellitus
2021     Agency for Care Effectiveness (ACE) Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active psoriatic arthritis
2021     Agency for Care Effectiveness (ACE) Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active ankylosing spondylitis
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2023     Agency for Care Effectiveness (ACE) Romosozumab and teriparatide for treating osteoporosis
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2023     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2023     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2023     Agency for Care Effectiveness (ACE) Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2024     Agency for Care Effectiveness (ACE) Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2024     Agency for Care Effectiveness (ACE) Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2024     Agency for Care Effectiveness (ACE) Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2024     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2023     Agency for Care Effectiveness (ACE) Presbyopia-correcting intraocular lenses for treating patients with cataract
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2023     Agency for Care Effectiveness (ACE) Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2023     Agency for Care Effectiveness (ACE) Aortic hybrid stent graft for treating complex aortic disease
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2023     Agency for Care Effectiveness (ACE) Cytosponge for the detection of patients with Barrett oesophagus
2023     Agency for Care Effectiveness (ACE) Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023     Agency for Care Effectiveness (ACE) Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023     Agency for Care Effectiveness (ACE) The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2023     Agency for Care Effectiveness (ACE) HeartFlow FFRCT for the diagnosis of coronary artery disease
2023     Agency for Care Effectiveness (ACE) Rapid to aid the diagnosis of patients suspected of stroke
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2023     Agency for Care Effectiveness (ACE) AcQMap for patients with cardiac arrhythmia
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma